A total of 82.4% of all patients received an angiotensin converting enzyme (ACE)-inhibitor or angiotensin-receptor blocker (77.4% of patients with DM vs. 85.6% without DM, p = 0.12), 87.7% received a beta blocker (86.4% of patients with DM vs. 88.3% without DM, p = 0.76), and 28.9% received a dihydropyridine calcium channel blocker (29.8% of patients with DM vs. 28.3% without DM, p = 0.83). This evidence concerns the gene ACE and diabetes mellitus.